Prolight secures first two European patents for Psyros™ technology
Prolight announces today that its first two European patents for the Psyros™ single molecule counting technology have been officially granted by the European Patent Office (EPO). Both patents are being protected in 17 European jurisdictions, covering a population of around 540 million people. The first patent is valid until 2040 and the second until 2041. […]
Study highlights speed of biomarker integration on Psyros POC platform
A collaborative research project between Prolight and St Thomas’ Hospital has demonstrated how quickly a cardiac biomarker assay for cMyC, can be transferred onto the Psyros™ point-of-care (POC) system. The study underscores the platform’s potential and its broader diagnostic applications beyond high-sensitive troponin. As part of Prolight’s on-going relationship with St Thomas’ Hospital, the Psyros™ […]
Prolight announces positive pre-clinical data
Prolight Diagnostics today announces positive results from the company’s pre-clinical validation study using plasma biobank samples. The results demonstrate that Prolight is on track to deliver its high-sensitivity troponin assay on the Psyros™ single-molecule-counting system. “The study results are highly encouraging and affirm the performance underlying the Psyros technology. Our system demonstrated very good clinical sensitivity […]
Prolight receives notice of allowance for MicroFlex patent
Prolight has received notice of allowance from the US Patent and Trademark Office (USPTO) for a patent application concerning the analytical device and reaction chamber for the company’s point-of-care system MicroFlex, in development by Prolight’s partner TTP (The Technology Partnership plc). The notice of allowance from USPTO means that the patent application is intended to be […]
The Psyros™ Cartridge Pilot Manufacturing line achieves another milestone!
Exciting developments are underway at FlexMedical Solutions with the arrival of new automation equipment to deliver our commitment to operational excellence, bringing us another step closer to large-scale production. We are proud of the hard work and collaboration between our teams and look forward to further strengthening our partnership as we move towards commercialization. Here’s a sneak […]
Prolight Diagnostics publishes year-end report 2024
Financial overview(figures in parentheses refer to the corresponding period in the previous year) Fourth quarter, October 1 – December 31, Q4 2024 Group• Net sales amounted to 0 (0).• Other operating income amounted to 15,317 (11,580) TSEK.• Profit after tax amounted to 2,011 (-110,094) TSEK.• Earnings per share before and after dilution: 0.00 (-0.32) SEK.• […]
Prolight receives second Notice of Intention to Grant from European Patent Office for Psyros™ technology
Prolight Diagnostics announces today that the company have received a Notice of Intention to Grant from the European Patent Office (EPO) for their second patent application related to the Psyros™ technology. This application (EP 4264266) is an extension to the core application (EP 3987287). This application is an extension of the core patent to include […]
Prolight receives Notice of Intention to Grant for core Psyros™ patent
Prolight Diagnostics announces today that they have received a Notice of Intention to Grant from the European Patent Office (EPO) for patent protection of their single molecule counting POC technology. This is the first application that will be granted in any territory for the Psyros™ technology. This application (EP 3987287) protects the fundamental measurement system […]
Prolight Diagnostics publishes investor letter for December 2024
In 2024, Prolight has achieved many business-critical milestones, positioning the company optimally for 2025 and on track for its planned commercial launch in 2026. link to the investor letter: https://prolightdx.com/PRLD-Investerarbrev-dec-2024-EN.pdf For further information, please contact:Ulf Bladin, CEOE-mail: info@prolightdx.comPhone: +46 73 582 39 87Company website: www.prolightdx.com About UsProlight Diagnostics AB develops innovative Point-of-Care (POC) systems. These […]
Prolight strengthens IP portfolio by additional patent application
Prolight is pleased to announce the filing of a sixth patent application relating to the Psyros™ high-sensitivity IVD platform. The Psyros™ system enables cost-effective high-sensitivity testing at the point-of-care through its single-molecule-counting technology. This new patent application enhances Prolight’s existing IP portfolio. The latest patent application builds upon the existing portfolio and allows any type […]
